BNP Paribas Asset Management
MLTX icon

BNP Paribas Asset Management’s MoonLake Immunotherapeutics MLTX Stock Holding History

BNP Paribas Asset Management’s Portfolio MLTX Stock Details MLTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$18.7K Buy
960
+37
+4% +$671 ﹤0.01% 2069
2026
Q1 		$17.2K Sell
923
-61,025
-99% -$1.01M ﹤0.01% 2079
2025
Q4 		$817K Buy
61,948
+61,676
+22,675% +$728K ﹤0.01% 1193
2025
Q3 		$2K Buy
272
+15
+6% +$782 ﹤0.01% 1859
2025
Q2 		$12K Buy
+257
New +$10.5K ﹤0.01% 1714

Other funds holding MLTX

DTC
Deep Track Capital Greenwich, Connecticut $6.87B AUM 205.24% 1-Year Est. Return
T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $153B AUM 38.14% 1-Year Est. Return
D.E. Shaw & Co
D.E. Shaw & Co New York $210B AUM 57.28% 1-Year Est. Return
CAM
Cormorant Asset Management Boston, Massachusetts $1.95B AUM 773.9% 1-Year Est. Return
JT
Jupiter Topco New York $245B AUM
LGM
Logos Global Management San Francisco, California $2.32B AUM 536.01% 1-Year Est. Return
WAM
Weiss Asset Management Boston, Massachusetts $9.54B AUM 55.06% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $875B AUM 40.91% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return
MB
MPM BioImpact Boston, Massachusetts $1.64B AUM 245.64% 1-Year Est. Return

BNP Paribas Asset Management's MLTX Position: Q2 2026 in Review

BNP Paribas Asset Management increased its MoonLake Immunotherapeutics (MLTX) stake by 4% in Q2 2026, buying an estimated $671 and bringing the position to 960 shares worth $18.7K. The position accounts for ﹤0.01% of the portfolio, ranked #2069.

BNP Paribas Asset Management first reported a position in MLTX in Q2 2025 and has held it in 5 quarters since. The position peaked at $817K in Q4 2025. 159 funds tracked by Wall St. Rank hold MLTX as of Q2 2026.

  • BNP Paribas Asset Management held 960 shares of MoonLake Immunotherapeutics worth $18.7K as of Q2 2026.
  • BNP Paribas Asset Management bought 37 MoonLake Immunotherapeutics shares in Q2 2026, an estimated $671.
  • MoonLake Immunotherapeutics made up ﹤0.01% of BNP Paribas Asset Management's portfolio in Q2 2026, its #2069 holding.
  • BNP Paribas Asset Management first reported a position in MoonLake Immunotherapeutics in Q2 2025 and has held it in 5 quarters since.
  • BNP Paribas Asset Management's MoonLake Immunotherapeutics position peaked at $817K in Q4 2025.
  • 159 funds tracked by Wall St. Rank held MoonLake Immunotherapeutics as of Q2 2026.

Based on BNP Paribas Asset Management's 13F filing for Q2 2026, filed 13 Aug 2026.